Lindsay Androski - 01 Jul 2022 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact for Lindsay Androski
Issuer symbol
N/A
Transactions as of
01 Jul 2022
Net transactions value
$0
Form type
4
Filing time
06 Jul 2022, 21:50:36 UTC
Next filing
31 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELOX Stock Options (Right to Buy) Award $0 +40,000 $0.000000 40,000 01 Jul 2022 Common Stock 40,000 $0.2500 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 50% of the underlying shares on July 1, 2023 and the remainder in twelve (12) equal monthly installments thereafter.